Eyeworld

EW CATARACT 28 Text goes here the AT LARA that includes smooth microphase technology to minimize light scatter and therefore halos and glare. The device has an aberra- tion neutral aspheric design and advanced chromatic correction for optimized contrast sensitivity. Outcomes with the AT LARA 829 revealed that in all 17 eyes the cumulative spherical equivalent was within –0.75 D to +0.75 D. In 88%, the spherical equivalent was between –0.5 D and +0.5 D, and in 82% it was within –0.25 D to +0.25 D. Just over half of the study eyes (53%) has a spherical equiv- alent within –0.125 D to +0.125 D, indicating high overall stability and demonstrating a high grade of optimization of the IOL calculation formulas. Visual acuity (monocular, n=17) outcomes revealed logMAR 0.00 for both corrected and uncorrected distance vision. Intermediate visual acuity (distance corrected) was log- MAR 0.05 at 90 cm, logMAR 0.10 at 80 cm, and logMAR 0.12 at 60 cm. Near (40 cm) visual outcomes (dis- tance corrected) were logMAR 0.40, and uncorrected near visual acuity was logMAR 0.49. The binocular (n=7) outcomes largely mirrored those achieved monocularly for distance and near visual acuities. The greatest differences were seen in intermediate visual acuity; binocular distance corrected intermediate vi- sion was logMAR –0.05 at 90 cm and logMAR 0.03 at 60 cm distances. "The defocus curve shows the range of focus that patients can see with this IOL," Dr. Kretz said. "As diopter values can be calculated in meters, it gives you a precise view of the distances the patients can see. With the AT LARA patients had a high level of visual acuity ranging from distance to 60 cm." Patient satisfaction Patient satisfaction and subjective observations are a big part of what makes for successful surgery with MFIOLs. Dr. Kretz employed the McAlinden questionnaire to gauge patient satisfaction. According to the questionnaire, 100% of the patients (n=10) were spectacle free for both distance and intermediate vision. When it came to reading glasses, 71% needed spectacles and 29% were spectacle free. When asked how often they wore glasses for distance or intermediate dis- tances, 86% responded "never" and 14% said "seldom." For near visual activities, 43% of the patients said that they "never" used glasses, 29% said "seldom," and 28% said "most of the time." When asked if they would pick a multifocal again if they could choose, 100% responded "yes." Multifocals have been known to cause unwanted optical phenomena, including halo, glare, and starbursts. While the AT LARA is optimized to reduce these effects, patient sen- sitivity can still play a substantial role in how optical phenomena are perceived. When asked how often they experienced glare, 71% of pa- tients said "occasionally," and 29% said "never." Halo was experienced "occasionally" in 29% of patients, "never" in 57%, and "quite often" in 14% of the study patients. Star- burst was noted "occasionally" in 29% and "never" in 71%. Glare was considered "sometimes" severe in 71% of patients and "never" severe in 29%. Halo was considered "occa- sionally" severe in 43% and "never" severe in 57%. Starburst was "never" severe in 72% of the study patients, "occasionally" severe in 14%, and "quite often" severe in 14%. When asked how bothersome they con- sidered these optical phenomena, 57% said the glare they experienced was "occasionally" bothersome, and 43% said it was "never" bothersome. Halo was "occasionally" bother- some in 43% and "never" in 57%. Starburst was "never" bothersome according to 71% of the patients and "occasionally" bothersome in 29%. "The new AT LARA EDOF IOL offers us an additional option for individualized patient care thanks to the enhancement of intermediate visual acuity," Dr. Kretz said. "This novel IOL design is associated with reduced optical phenomena, accord- ing to the McAlinden questionnaire results, with increased optical per- formance for distance and interme- diate ranges. It causes less halo and glare perception in my experience than the Tecnis Symfony EDOF IOL [Johnson & Johnson Vision, Santa Ana, California]. A mix and match approach may be a good option for further enhancement of the range of focus, which we did not opt for in this small sample size." EW Editors' note: Dr. Kretz has financial interests with Alimera Sciences (Al- pharetta, Georgia), Carl Zeiss Meditec, Glaukos (San Clemente, California), Oculentis (Berlin, Germany), and Poly- tech Domilens (Rossdorf, Germany). Contact information Kretz: f.kretz@augenklinik.de Novel continued from page 26

• Cover
• Blank Page
• Blank Page (1)